Lnc2Cancer

Experimentally Supported Human LncRNA and Cancer Associations Database

LncRNA centric

Cancer centric

Advanced search

Drug resistant

Circulating

Prognosis

Detail


   LncRNA Name TUG1
   Synonyms TUG1, LINC00080, NCRNA00080, TI-227H, FLJ20618
   Region GRCh38_22:30969245-30979395    Sequence
   Ensembl ENSG00000253352
   RefSeq NR_002323
   Circulating
   Drug-resisitant
   Prognostic
   MiRNA
   Variant
   TF
   Methylation
   Cancer Name intrahepatic cholangiocarcinoma
   ICD-0-3 C22  M8160/3
   Methods qPCR, Western blot, Luciferase reporter assay etc.
   Sample cell lines (HuH28, HuCCT1, RBE, HCCC-9810)
   Expression Pattern up-regulated
   Function Description

In this study, we investigated the role of TUG1 in the pathogenesis of intrahepatic cholangiocarcinoma (ICC).TUG1 is upregulated in ICC samples, which correlates with poor prognosis and adverse clinical pathological characteristics. Knockdown of TUG1 inhibited the proliferation, motility, and invasiveness of cultured ICC cells, and decreased tumor burden in a xenograft mouse model. When we explored the mechanisms underlying these effects, we found that TUG1 acts as an endogenous competing RNA (ceRNA) that â??spongesâ?? miR-145, thereby preventing the degradation of Sirt3 mRNA and increasing expression of Sirt3 and GDH proteins. Accordingly, glutamine consumption, a-KG production, and ATP levels were dramatically decreased by TUG1 knockdown in ICC cells, and this effect was reversed by miR-145 inhibition. These findings indicate that the TUG1/miR-145/Sirt3/GDH regulatory network may provide a novel therapeutic strategy for treatment of ICC.

   Pubmed ID 29371936
   Year 2017
   Title LncRNA TUG1 sponges miR-145 to promote cancer progression and regulate glutamine metabolism via Sirt3/GDH axis
   External Links
   Links for  TUG1 GenBank       HGNC       lncrnadb       Noncode
   Links for  intrahepatic cholangiocarcinoma Omim       Cosmic

CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.